Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Thrombosis Prevention and Anticoagulation Management in the Pediatric Patient with Congenital Heart Disease

Thrombosis Prevention and Anticoagulation Management in the Pediatric Patient with Congenital... Thrombosis is one of the most frequent complications affecting children with congenital heart disease (CHD). Palliative and reparative cardiac surgeries are some of the main players contributing to the thrombosis risk in this patient population. Additional risk factors related to the CHD itself (e.g., cardiac dysfunction, arrhythmias, and polycythemia in cyanotic cardiac disorders) can contribute to thrombogenicity alone or combined with other factors. Thrombotic complications have been recognized as a significant cause of morbidity and mortality in this patient population. Here, we provide an overview of the pathophysiology and risk factors for thrombosis as well as the indications for and use of different anticoagulation, antiplatelet, and thrombolytic agents. In addition, we describe some of most common thrombotic complications and their management in the pediatric CHD population. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cardiology and Therapy Springer Journals

Thrombosis Prevention and Anticoagulation Management in the Pediatric Patient with Congenital Heart Disease

Loading next page...
 
/lp/springer-journals/thrombosis-prevention-and-anticoagulation-management-in-the-pediatric-3Wo70IHHfo

References (139)

Publisher
Springer Journals
Copyright
Copyright © The Author(s) 2021
ISSN
2193-8261
eISSN
2193-6544
DOI
10.1007/s40119-021-00228-4
Publisher site
See Article on Publisher Site

Abstract

Thrombosis is one of the most frequent complications affecting children with congenital heart disease (CHD). Palliative and reparative cardiac surgeries are some of the main players contributing to the thrombosis risk in this patient population. Additional risk factors related to the CHD itself (e.g., cardiac dysfunction, arrhythmias, and polycythemia in cyanotic cardiac disorders) can contribute to thrombogenicity alone or combined with other factors. Thrombotic complications have been recognized as a significant cause of morbidity and mortality in this patient population. Here, we provide an overview of the pathophysiology and risk factors for thrombosis as well as the indications for and use of different anticoagulation, antiplatelet, and thrombolytic agents. In addition, we describe some of most common thrombotic complications and their management in the pediatric CHD population.

Journal

Cardiology and TherapySpringer Journals

Published: Dec 1, 2021

Keywords: Anticoagulation; Thrombosis; Congenital heart disease; Warfarin; Heparin; Aspirin

There are no references for this article.